Oxford based Mirada Medical has signed new contracts to install its DLCExpert AI system at Royal Surrey NHS Foundation Trust, Northwestern Hospital (IL), City of Hope (CA) and CHU Liège.
The company uses AI-powered autocontouring software for cancer treatment planning.
A study conducted in 2018 explored the strategy for using software to reduce contouring time, with a median time of 20 minutes for manual contouring, the total median time saved was 7.8 minutes when using atlas-based contouring and 10 min for deep learning contouring. Both atlas based and deep learning adjustment times were significantly lower than manual contouring time for all organs at risk except for the left lung and esophagus of the atlas based contouring.
Dr. Amato J. Giaccia, Director of the Institute of Radiation Oncology at Oxford University “I believe that automated contouring of organs at risk using AI is revolutionising the radiotherapy planning process. Not only can AI free up doctors’ time, which is a huge benefit for patients, but it may also enable better outcomes.”
“This is not just about producing faster workflows, it’s also about the overall quality of treatment plans, as AI will be able to help identify normal tissue and preserve at risk tissue. This, in turn, will help deliver greater personalised care, while potentially contributing to improved outcomes.”
Charlotte Brouwer, Medical Physicist at the Department of Radiation Oncology, University Medical Center Groningen, said “The collaboration between UMC Groningen and Mirada Medical has produced autocontouring models that encode according to consensus guidelines, established by an international panel of experts for organs at risk. These DLCExpert models are now deployed in our routine clinical workflows, forming a key part of our treatment planning for all patients with cancers in the head and neck or prostate regions.”
“Thanks to DLCExpert, we now enjoy measurable and consistent time-savings, which we expect to translate to other institutions. Perhaps the clearest indications of their clinical acceptance were the loud objections of our RT planning team when the models were briefly unavailable during routine maintenance!”
Mirada Medical CEO, Hugh Bettesworth said “I am delighted that Mirada’s technology is being deployed so widely and that patients are benefitting from it every day. We hear a lot of talk about bringing artificial intelligence to medicine – I am immensely proud that it is Mirada’s brilliant team of scientists and engineers who have worked with our customers, our clinical advisors, and the regulators in the USA and Europe, and have delivered every-patient clinical advances for cancer treatment planning using artificial intelligence.”
